USA - engelsk - NLM (National Library of Medicine)

redpharm drug inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal i

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant stap

USA - engelsk - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal i

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - cloxacillin as the benzathine salt; brilliant blue fcf - misc. intra mammary - cloxacillin as the benzathine salt antibiotic active 600.0 mg/3.6gs; brilliant blue fcf dye-blue other 25.0 mg/3.6gs - antibiotic & related - dairy cattle | bovine | breeders | calves | dairy cow | growers | lactating cow | milking cow - corynebacterium spp. | mastitis | staphylococcus spp. | streptococcus spp. | bacterial canker | staphylococcosis | subclinical mastitis

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - cloxacillin as the benzathine salt - misc. intra mammary - cloxacillin as the benzathine salt antibiotic active 600.0 mg/3.6gd - antibiotic & related - dairy cattle | bovine | breeders | calves | dairy cow | growers | lactating cow | milking cow - mastitis | subclinical mastitis

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - cloxacillin as the benzathine salt - misc. aural, ophthalmic, oro/naso pharyngeal - cloxacillin as the benzathine salt antibiotic active 833.0 mg/sg - ophthalmic preparations - cat | cattle | dog | horse | sheep | beef | bitch | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | castra - bacterial kerato conjunctivitis

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - cloxacillin as the benzathine salt - misc. intra mammary - cloxacillin as the benzathine salt antibiotic active 166.7 mg/g - antibiotic & related - cow | bovine | female cattle - mastitis | subclinical mastitis

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

ΚΟΠΕΡ Α.Ε. ΑΡΙΣΤΟΒΟΥΛΟΥ 64, 11853 Κ. ΠΕΤΡΑΛΩΝΑ 3462102 3462108 - flucloxacillin sodium - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 1000mg/vial - flucloxacillin sodium 1.088,13mg - flucloxacillin

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

ΚΟΠΕΡ Α.Ε. ΑΡΙΣΤΟΒΟΥΛΟΥ 64, 11853 Κ. ΠΕΤΡΑΛΩΝΑ 3462102 3462108 - flucloxacillin sodium - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 500mg/vial - flucloxacillin sodium 544,07mg - flucloxacillin

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

ΚΟΠΕΡ Α.Ε. ΑΡΙΣΤΟΒΟΥΛΟΥ 64, 11853 Κ. ΠΕΤΡΑΛΩΝΑ 3462102 3462108 - flucloxacillin sodium - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 250mg/vial - flucloxacillin sodium 272,03mg - flucloxacillin